RGD Reference Report - Roles of TNF-alpha, GSK-3beta and RANKL in the occurrence and development of diabetic osteoporosis. - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

Roles of TNF-alpha, GSK-3beta and RANKL in the occurrence and development of diabetic osteoporosis.

Authors: Qi, J  Hu, KS  Yang, HL 
Citation: Qi J, etal., Int J Clin Exp Pathol. 2015 Oct 1;8(10):11995-2004. eCollection 2015.
RGD ID: 11555176
Pubmed: PMID:26722385   (View Abstract at PubMed)
PMCID: PMC4680330   (View Article at PubMed Central)

OBJECTIVE: To investigate the roles of TNF-alpha, GSK-3beta and RANKL in the occurrence and development of diabetic osteoporosis. METHODS: Diabetic rat model was established; tissue section technology was used to observe the situation of osteoporosis in diabetic rats; rat serum levels of OC, RANKL, GSK-3beta, P38mapk, TNF-alpha and INS were detected by Elisa assay; osteoblasts and osteoclasts were primarily cultured and identified by immunohistochemistry and tartrate-resistant acid phosphatase (TRAP) staining respectively. The effects of GSK-3beta inhibitors, lithium chloride, TNF-alpha antagonists and RANKL antagonists on the proliferation of osteoblasts and osteoclasts were evaluated; quantitative PCR was used to assess the effects of GSK-3beta inhibitors, lithium chloride, on TNF-alpha and RANKL gene expression in osteoblasts and osteoclasts, and the effects of TNF-alpha and RANKL antagonists on GSK-3beta gene expression in osteoblasts and osteoclasts. RESULTS: Diabetic rat model was successfully established; osteoblasts and osteoclasts were successfully isolated and cultured. Elisa experiments showed that in diabetic model group, the levels of RANKL, GSK-3beta, P38mapk and TNF-alpha were significantly increased, while the levels of osteocalcin (OC) and insulin (INS) were significantly reduced; MTT results showed that osteoclast proliferation in GSK-3beta inhibitor and lithium chloride groups were weaker than the untreated group, while osteoclast proliferation in TNF-alpha antagonist group and RANKL antagonist Group was very close to the untreated group. Osteoblast proliferation in GSK-3beta inhibitor and lithium chloride groups were weaker than the untreated group, while osteoblast proliferation in TNF-alpha antagonist group and RANKL antagonist group was higher than the untreated group. In all of the corresponding groups, cell proliferation in the diabetic group was stronger than the untreated group. In GSK-3beta inhibitor and lithium oxide groups, TNF-alpha and RANKL gene expression levels were elevated, but TNF-alpha and RANKL gene expression levels in the diabetic group were slightly lower than the control group. GSK-3beta gene expression level in TNF-alpha antagonist group and RANKL antagonist group was reduced; GSK-3beta gene expression level in diabetic group was lower than the control group. CONCLUSION: In diabetic rats, TNF-alpha, GSK-3beta and RANKL levels were elevated; GSK-3beta could promote the proliferation of osteoblasts and osteoclasts, and inhibit the expression of TNF-alpha and RANKL; TNF-alpha and RANKL can suppress the proliferation of osteoblasts while had little effect on osteoclast proliferation; they also can promote the GSK-3beta gene expression; interactions between the three broke the balance between osteoblasts and osteoclasts, leading to osteoporosis.

Gene Ontology Annotations    Click to see Annotation Detail View

Biological Process
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
positive regulation of osteoblast proliferation  IMP 11555176 RGD 
positive regulation of osteoclast proliferation  IMP 11555176 RGD 

Objects Annotated

Genes (Rattus norvegicus)
Gsk3b  (glycogen synthase kinase 3 beta)


Additional Information